Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
136 participants
INTERVENTIONAL
2014-03-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
omega-3 fatty acids
3 capsules each day during 8 weeks
omega-3 fatty acids
highly dosed in EPA
placebo
3 capsules each day during 8 weeks
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
omega-3 fatty acids
highly dosed in EPA
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* complaining of hot flashes
* social security affiliation
* informed consent form signed
Exclusion Criteria
* allergy to omega-3 fatty acids
* allergy to sea products
* High consumption of fat fish or produced by the sea
* iatrogenic hot flashes
* actual omega-3 fatty acids consumption or in the 3 last months.
* consumption of drug or other products for hot flashes in the last month
* protected persons (L1121-5 to L1121-8 of French Public health code)
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre d'Investigation Clinique de Grenoble CIC1406
UNKNOWN
Vivatech
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Luc CRACOWSKI, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Centre d'investigation clinique CIC1406
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'investigation clinique CIC1406
Grenoble Cedex9, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DCIC 13 15
Identifier Type: -
Identifier Source: org_study_id